01—Abstract
Summary
Summary of the 8-K filed August 21, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported on Form 8-K that on August 16, 2024, it entered into a Transaction Agreement, approved by a special committee of independent and disinterested directors, to form and fund GondolaBio, LLC, a joint venture for researching, developing, manufacturing and commercializing pharmaceutical products, including programs the Company contributed.
The Transaction closed on the date the agreement was signed. The Company contributed certain early-stage clinical and pre-clinical programs in Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex. Certain third-party investors have committed $300 milliona of tranched financing to GondolaBio.
The investor syndicate includes Viking Global Investors LP, Patient Square Capital, Sequoia Capital, Frazier Life Sciences, Cormorant Asset Management, Aisling Capital, and an entity owned by Neil Kumar, the Company's Chief Executive Officer. The Company's initial interest in GondolaBio will be approximately 45%b, subject to reduction as additional capital tranches are funded. On the same date, BridgeBio Pharma LLC, a wholly owned subsidiary, became a party to the Amended and Restated Limited Liability Company Agreement of GondolaBio, which sets out the members' economic and governance rights.
Goldman Sachs & Co. LLC advised the special committee as financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP advised the Company. The Transaction Agreement and LLC Agreement are filed as Exhibits 10.1 and 10.2.
02—Key points
Key Highlights
- On August 16, 2024, BridgeBio entered into a Transaction Agreement to form GondolaBio, LLC, a joint venture, and the transaction closed the same day.
- The Company contributed early-stage clinical and pre-clinical programs in Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.
- Investors have committed $300 million of tranched financing to GondolaBio.
- BridgeBio's initial interest in GondolaBio will be approximately 45%, subject to reduction as additional capital tranches are funded.
- Investors include Viking Global Investors LP, Patient Square Capital, Sequoia Capital, Frazier Life Sciences, Cormorant Asset Management, Aisling Capital, and an entity owned by CEO Neil Kumar.
- The transaction was approved on the recommendation of a special committee of independent and disinterested directors.
- BridgeBio Pharma LLC, a wholly owned subsidiary, became a party to the GondolaBio Amended and Restated LLC Agreement.
03—Questions
Frequently Asked Questions
What is GondolaBio, LLC?
GondolaBio is a Delaware limited liability company formed as a joint venture to research, develop, manufacture and commercialize pharmaceutical products, including programs contributed by BridgeBio Pharma, Inc.
Which programs did BridgeBio contribute to GondolaBio?
BridgeBio contributed certain early-stage clinical and pre-clinical stage programs in the areas of Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.
How much financing have outside investors committed?
The Investors have committed $300 million of tranched financing to GondolaBio.
Does the CEO have a stake in this transaction?
Yes. An entity owned by Neil Kumar, the Company's Chief Executive Officer, is among the Investors providing financing to GondolaBio. The transaction was reviewed by a special committee of independent and disinterested directors.
What ownership will BridgeBio hold in GondolaBio?
BridgeBio's initial interest in GondolaBio will be approximately 45%, which will be subject to reduction as additional tranches of capital contributions are funded.
04—Continue